Mark Herman is an Endocrinology/Metabolic physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
330 Brookline Ave
E/cls 735
Boston, MA 022155400
Telephone
617-667-9344Provider last certified this registry record 5 Apr 2022.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
85.8%GLP-1 receptor agonist50.3%Ozempic45%Mounjaro40%Trulicity15%Part D<11 patientsInsulin Analog30.1%Lantus Solostar29%Insulin Lispro Kwikpen U-10017%Toujeo Max Solostar15%Humalog Kwikpen U-10014%Toujeo Solostar13%Novolog Flexpen12%Part D<11 patients+ 1 more class in this area
Hormonal (systemic)
10.3%l-Thyroxine10.3%Levothyroxine Sodium100%Part D<11 patientsSensory organs
4%Corticosteroid4%Hydrocortisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2006–2016 per NIH RePORTER. The latest:
- The Role of ChREBP in Fructose Induced Metabolic Disease
Beth Israel Deaconess Medical Center
FY2016$265,350R01DK100425 - The Role of ChREBP in Fructose Induced Metabolic Disease
Beth Israel Deaconess Medical Center
FY2015$378,450R01DK100425 - The Role of ChREBP in Fructose Induced Metabolic Disease
Beth Israel Deaconess Medical Center
FY2014$378,450R01DK100425
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”